Pharmacological modulation of mGluR5 improves dyskinesias mediated by D1 but not D2 receptor stimulation.
Objective: To determine whether pharmacological inhibition of metabotropic glutamate receptor type 5 (mGluR5) can improve dyskinesias mediated by D1- or D2-type dopamine (DA) receptors (D1R…Adding cues to a rat gambling task potentiates the increase in premature responding in response to chronic D2/3 agonist ropinirole without mitigating preference for risk
Objective: Investigating the effect of chronic administration of the dopamine D2/3 agonist ropinirole on a cued model of gambling behaviour in rats. Background: Dopamine D2/3 agonists…Neuroticism and depression is associated with impulse control disorder in Parkinson’s disease: a controlled study
Objective: Cross-sectional assessment of personality trait, impulsivity, depression and anxiety collected prospectively in Parkinson’s disease (PD) with impulse control disorders (PD-ICD) compared to a matched…Exome sequencing in patients with impulse control disorders in Parkinson’s disease: a pilot study
Objective: To identify genetic variants associated with impulse control disorders (ICD) in Parkinson’s disease (PD) Background: ICD is frequently associated with dopamine agonist (DA) therapy…Specific Bdnf variants are associated with suboptimal response to levodopa but not to other dopaminergic medications or deep brain stimulation in Parkinson’s disease
Objective: We examined the impact of rs6265 and other brain-derived neurotrophic factor (Bdnf) variants in two subject cohorts: 1) early-stage Parkinson’s disease (PD) subjects from…Dopamine agonist therapy mediates relationship between psychomotor inhibition and behavioral impulsivity in Parkinson’s disease.
Objective: Evaluate relationship between psychomotor inhibition and behavioral impulsivity in Parkinson’s disease (PD). Background: Impulse control disorders can be challenging iatrogenic effects of dopamine agonist…Genetics of impulse control disorders in Parkinson’s disease: a case control study
Objective: To investigate the association between candidate genes and impulse control disorders (ICD) in patients with Parkinson’s disease. Background: ICD are frequently associated with dopaminergic…Longitudinal analysis of the relation of dopamine agonist use with impulse control disorders in Parkinson’s disease
Objective: To investigate the longitudinal relationship between dopaminergic therapies and impulse control disorders (ICD) in PD. Background: ICD are frequently associated with dopaminergic therapy, particularly dopamine…Impulse control disorder and associated clinical factors in drug-naïve Parkinson’s disease.
Objective: To investigate various clinical factors associated with Impulse Control Disorders (ICD) in Parkinson's disease (PD) patients who have never been exposed to Dopamine Replacement…Double-blind, randomized, placebo-controlled, Phase III study (TOLEDO) to evaluate the efficacy of apomorphine subcutaneous infusion in reducing OFF time in Parkinson’s disease patients with motor fluctuations not well controlled on optimized conventional treatment
Objective: The TOLEDO Study (NCT02006121) is a prospective, randomized, multicenter, double-blind, Phase III trial undertaken to investigate the efficacy of apomorphine subcutaneous infusion (APO) compared…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 15
- Next Page »